NCT02193139View on ClinicalTrials.gov

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Hyperhidrosis
Interventions
DRUG

WL8713, 6 mg

DRUG

WL8713, 12 mg

DRUG

WL8713, 18 mg

DRUG

WL8713, 24 mg

DRUG

Placebo

Trial Locations (1)

Unknown

Watson Clinical Site, San Diego

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT02193139 - Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis | Biotech Hunter | Biotech Hunter